Impact of Soluble BCMA and Non–T-Cell Factors on Refractoriness to BCMA-Targeting T-Cell Engagers in Multiple Myeloma

Medicine, Hematology, Oncology, Life Sciences, Immunology,
Soluble BCMA   Multiple Myeloma   T-Cell Engagers   Refractoriness   Tumor Burden   Surface Antigen Density   Therapeutic Optimization  

The Impact of Soluble B-Cell Maturation Antigen (sBCMA) on Multiple Myeloma Therapy: Interpreting the Latest Research Findings In recent years, cell-based immunotherapies have demonstrated enormous promise in the treatment of multiple myeloma (MM). Among these, BCMA-targeting T-cell engagers (TCEs) and chimeric antigen receptor (CAR) T-cell therapi...

Emapalumab Therapy for Hemophagocytic Lymphohistiocytosis Before Reduced-Intensity Transplantation Improves Chimerism

Medicine, Pediatrics, Hematology, Life Sciences, Immunology,
Hemophagocytic Lymphohistiocytosis   Chimerism   Reduced-Intensity Transplantation   Emapalumab   Intervention-Free Survival  

Research Report on Pre-HCT Emapalumab Therapy Improving Donor Chimerism in Children with HLH Background and Objective of the Study Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune disorder caused by pathological immune activation. The primary mechanism involves the functional deficiency of cytotoxic activity in natural killer (...

Prognostic Impact of Cytogenetic Abnormalities Detected by FISH in AL Amyloidosis with Daratumumab-Based Frontline Therapy

Medicine, Hematology, Oncology, Life Sciences, Immunology,
AL amyloidosis   daratumumab   cytogenetic abnormalities   FISH   prognosis   frontline therapy   hematologic response  

Review of the Impact of FISH-Detected Cytogenetic Abnormalities on Prognosis in AL Amyloidosis in the Era of Daratumumab Therapy Background Immunoglobulin light chain (AL) amyloidosis is a rare disease characterized by organ dysfunction caused by the deposition of light chain proteins secreted by abnormal plasma cells. However, the heterogeneous cl...

Classical Pathway Stimulus in Complement-Mediated Thrombotic Microangiopathy

Medicine, Hematology, Life Sciences, Immunology,
Complement-mediated thrombotic microangiopathy   Classical pathway   IgM   Complement biosensors   Diagnosis   Therapeutic monitoring   Complement inhibition  

Utilizing Complement Biosensors to Explore Novel Mechanisms in Complement-Mediated Thrombotic Microangiopathy Background and Necessity Complement-mediated thrombotic microangiopathy (CM-TMA) is a thrombotic microangiopathy caused by complement system dysregulation, with complex clinical manifestations including subtypes such as atypical hemolytic u...

Rates of Strokes in Californians with Sickle Cell Disease in the Post-STOP Era

Medicine, Neurology, Hematology,
sickle cell disease   stroke   STOP trial   California   cerebrovascular events  

Changes in Stroke Incidence in Californians with Sickle Cell Disease: A Population-Based Study in the Context of the STOP Trial Background and Objective Sickle Cell Disease (SCD) is a hereditary blood disorder characterized by abnormal hemoglobin, causing red blood cells to deform into a sickle shape under low-oxygen conditions. This deformation in...

Follicular Lymphoma Comprises Germinal Center–Like and Memory-Like Molecular Subtypes with Prognostic Significance

Medicine, Hematology, Oncology, Life Sciences, Immunology,
follicular lymphoma   molecular subtypes   prognosis   immunohistochemistry   gene expression   treatment response   precision medicine  

Progress in Molecular Classification of Follicular Lymphoma: A Dual Typing Predictive Model Based on RNA Sequencing and Immunohistochemistry Follicular Lymphoma (FL) is a B-cell malignancy characterized by a slow clinical progression, with a median overall survival extending up to 20 years. However, the heterogeneous nature of FL leads to significa...